Trastuzumab: Unusual responses and toxicities

Future Oncology

Volumn 5, Issue 6, 2009, Pages 779-784

  Ahamed, Eliyaz ^a   Mauri, Francesco A ^b   Pakter, Grant ^a   Lim, Adrian ^a   Stebbing, Justin ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; HER2; Pulmonary toxicity; Trastuzumab

Indexed keywords

ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CAPECITABINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; TAMOXIFEN; TRASTUZUMAB; VANCOMYCIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ANKLE EDEMA; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COUGHING; DRUG RESPONSE; DYSPNEA; FEMALE; FEVER; HUMAN; LETHARGY; LIVER METASTASIS; LYMPHADENOPATHY; METASTASIS POTENTIAL; MONOTHERAPY; ORGANIZING PNEUMONIA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS BLEEDING; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LUNG; MIDDLE AGED; PACLITAXEL; PNEUMONIA; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 70349220037     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.55     Document Type: Article

References (20)

1. Slamon DJ, Clark GM, Wong SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
2. Vogel CL, Cobleigh MA, Tripathy D et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
3. +/MCB) markedly increases anticancer activity: a randomized, multinational controlled Phase III trial. Presented at: ASCO Annual Meeting. LA, USA, May 16-19 (1994) (Abstract 377).
4. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
5. Slamon D EW, Robert N, Pienkowski P et al.: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of Her2 positive early breast cancer patients: second interims efficacy analysis. Breast Cancer Res. Treat. 100(Suppl. I) (2006) (Abstract 52).
6. Smith I, Procter M, Gelber RD et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555), 29-36 (2007).
7. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353(16), 1734-1736 (2005).
8. Cancello G, Montagna E, D'Agostino D et al.: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 10(4), R60 (2008).
9. von Minckwitz G, du Bois A, Schmidt M et al.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J. Clin. Oncol. 27(12), 1999-2006 (2009).
10. + metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol. 26(Suppl. 20) (2008) (Abstract 1015).
11. Fujimoto-Ouchi K, Sekiguchi F, Mori K: Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. AACR Meeting Abstracts 2005(1) (2005) (Abstract 5062).
12. + metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, December 10-14 (2008) (Poster 3142).
13. Ellis LM, Haller DG: Bevacizumab beyond progression: does this make sense? J. Clin. Oncol. 26(33), 5313-5315 (2008)
14. Vahid B, Mehrotra A: Trastuzumab (Herceptin)-associated lung injury. Respirology 11(5), 655-658 (2006).
15. Pepels MJ, Boomars KA, van Kimmenade R, Hupperets PS: Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res. Treat. 113(3), 609-612 (2009).
16. Radzikowska E, Szozepulska E, Chabowski M, Bestry I: Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur. Respir. J. 21(3), 552-555 (2003).
17. Nanda A, Dias-Santagata D, Stubbs H et al.: Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer. Clin. Lung Cancer 9(5), 285-287 (2008).
18. Cameron D, Casey M, Press M et al.: A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112(3), 533-543 (2008).
19. Gelmon KA, Fumoleau P, Verma S et al.: Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 1026).
20. + metastatic breast cancer (MBC): final results. J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 1017).